Latest news
The CHAMP Regimen of Cabazitaxel-Carboplatin plus Ipilimumab-Nivolumab for Aggressive Prostate Cancer - Andrew Armstrong - UroTodayUroToday · Mon, 03 Aug 2026 21:19:56 GMTBundang CHA study sheds light on nivolumab-ipilimumab outcomes in high-risk liver cancer - koreabiomed.comkoreabiomed.com · Mon, 27 Jul 2026 02:12:40 GMT